Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Okuma

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Oncology Letters|August 18, 2020
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervixTakaaki Mizuno, Yuki Kojima, Kan Yonemori, et al.
Oncology Letters|October 30, 2020
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancerTakaaki Mizuno, Yuki Kojima, Kan Yonemori, et al.
Gynecologic Oncology Reports|December 6, 2023
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinomaYuki Kojima, Hiroshi Yoshida, Toshihiro Okuya, et al.
Anticancer Research|April 27, 2024
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker AnalysisToru Imai, Yuki Kojima, Tatsunori Shimoi, et al.
Cancer Cell International|February 4, 2023
Changes in HER3 expression profiles between primary and recurrent gynecological cancersYuki Kojima, Kazuki Sudo, Hiroshi Yoshida, et al.
Cancers|May 28, 2022
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse GliomasTakaki Omura, Masamichi Takahashi, Makoto Ohno, et al.
Blood Cancer Journal|April 14, 2026
Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosisPaul G Kemps, Jennifer L Picarsic, Sébastien Héritier, et al.
Cancer Discovery|January 8, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivatorsFerran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Oncology Letters|August 18, 2020
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervixTakaaki Mizuno, Yuki Kojima, Kan Yonemori, et al.
Oncology Letters|October 30, 2020
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancerTakaaki Mizuno, Yuki Kojima, Kan Yonemori, et al.
Gynecologic Oncology Reports|December 6, 2023
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinomaYuki Kojima, Hiroshi Yoshida, Toshihiro Okuya, et al.
Anticancer Research|April 27, 2024
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker AnalysisToru Imai, Yuki Kojima, Tatsunori Shimoi, et al.
Cancer Cell International|February 4, 2023
Changes in HER3 expression profiles between primary and recurrent gynecological cancersYuki Kojima, Kazuki Sudo, Hiroshi Yoshida, et al.
Cancers|May 28, 2022
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse GliomasTakaki Omura, Masamichi Takahashi, Makoto Ohno, et al.
Blood Cancer Journal|April 14, 2026
Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosisPaul G Kemps, Jennifer L Picarsic, Sébastien Héritier, et al.
Cancer Discovery|January 8, 2026
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivatorsFerran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel, et al.
Pageof 5